Plain language summary
C-reactive protein (CRP) is a blood marker of inflammation and is frequently elevated in chronic conditions such as heart disease, obesity and Type 2 diabetes. Some strains of probiotics (bacteria that exert health benefits) are thought to act as anti-inflammatory agents through various mechanisms. This systematic review and meta-analysis of 20 randomised controlled trials (RCTs) aimed to investigate the effects of probiotic supplementation on CRP levels as one measure of inflammation. The meta-analysis indicates that probiotic supplementation with various strains of bacteria has a significant impact on serum CRP levels, with a weighted mean difference of -1.35mg/l. Whilst positive impacts were also seen for interleukin-10 and tumour necrosis factor-alpha (other markers of inflammation) with probiotics, these did not reach significance. The authors of this study point out that the results need to be interpreted with caution owing to the wide variety of study types, study size, probiotic strains and health outcomes measured in the included RCTs. However, Nutrition Practitioners working with clients with raised CRP levels may want to investigate the use of certain probiotic strains as part of an anti-inflammatory protocol.
Abstract
We conducted this systematic review and meta-analysis of prospective studies to determine the effect of probiotic administration on serum C-reactive protein (CRP) concentrations. We searched PubMed-Medline, Web of Science, the Cochrane, and Google Scholar databases (until May 2016) to identify prospective studies evaluating the impact of probiotic administration on CRP. We used a random effects models and generic inverse variance methods to synthesize quantitative data, followed by a leave-one-out method for sensitivity analysis. The systematic review registration number was: CRD42016039457. From a total of 425 entries identified via searches, 20 studies were included in the final analysis. The meta-analysis indicated a significant reduction in serum CRP following probiotic administration with a weighted mean difference (WMD) of -1.35 mg/L, (95% confidence interval (CI) -2.15 to -0.55, I² 65.1%). The WMDs for interleukin 10 (IL10) was -1.65 pg/dL, (95% CI -3.45 to 0.14, I² 3.1%), and -0.45 pg/mL, (95% CI -1.38 to 0.48, I² 10.2%) for tumor necrosis factor alpha (TNF-α). These findings were robust in sensitivity analyses. This meta-analysis suggests that probiotic administration may significantly reduce serum CRP while having no significant effect on serum IL10 and TNF-α.
Methodological quality
Allocation concealment
:
Not applicable
